The main aims of this study were to evaluate the patient reported outcomes (PROs), safety and efficacy, after 6-year (66 - 78 months) from the binocular implantation of the AT LISA tri 839MP. A secondary aim was to evaluate new metrics such as contrast sensitivity defocus curves and light distortion analysis.

Retrospective cross-sectional study with two stages:

• Phone call interview:

First stage included patient reported outcomes of visual function, spectacle independence and satisfaction through questionnaires conducted by a phone call in all the patients implanted in our center with AT LISA 839MP from March 2014 to June 2015 (n=92) which accomplished inclusion / exclusion criteria and were able to be contacted by phone (n=62).

The incidence of Nd-YAG capsulotomy was retrospectively evaluated through the revision of the medical history, in patients for which capsulotomy was conducted in our center, or a question, for those treated in another center.

• Study visit:

Second stage included the consecutive invitation of these phone interviewed patients to a visit in our center for a long-term visual performance assessment up to accomplish the required sample size (n=37).

Corrected and uncorrected monocular visual acuities were the primary end-points for testing non-inferiority hypothesis in comparison to 12-month follow-up mean results reported in the literature. Secondary variables of assessment were contrast sensitivity defocus curve and light distortion analysis.

Inclusion Criteria:

• Phone call interview:

  • Patients of either sex, 45 years of age or older at the time of surgery and less than 80 years of age at the time of the phone call.
  • Patients implanted bilaterally with the AT LISA 839MP MIOL in the capsular bag.
  • No surgical complications reported in the clinical history that could affect postoperative visual acuity: damage to the capsular bag, intraocular hemorrhage, etc.
  • Operated between 66 months from the first implanted eye and up to 78 months from the surgery of the second eye
  • Patient able to hear, understand and give express consent orally.

• Study visit:

  • To have participated in the first stage of the study corresponding to the phone call interview.
  • Irregular astigmatism in either eye measured with corneal tomography (total high-order corneal aberrations at 4 mm < 0.5 μm).
  • Patient able to read, understand and provide a written informed consent form.
  • Sufficient availability, willingness, skills, and cognitive awareness to comply with follow-up/study procedures and study visits.

Exclusion Criteria:

• Phone call interview:

  • Any eye disease documented in the patient's clinical history that may potentially cause a loss of visual acuity or diplopia: Active or recurrent pathology of the anterior segment (chronic uveitis, iritis, iridocyclitis, rubeosis iridis, uncontrolled glaucoma, etc.), retinal or optic nerve pathologies such as diabetic retinopathy, macular degeneration, etc.
  • Eye surgery (including laser refractive surgery) performed before or after the operation with the intraocular lens.

• Study Visit:

  • PCO ≥ 2 according to surgeon criteria that produces a loss of CDVA ≥ 0.2 logMAR
  • Any eye disorder that can potentially cause a loss of visual acuity or diplopia: Active or recurrent pathology of the anterior segment (chronic uveitis, iritis, iridocyclitis, rubeosis iridis, uncontrolled glaucoma, etc.), retinal or optic nerve pathologies such as diabetic retinopathy, macular degeneration, etc.
  • Eye surgery (including laser refractive surgery) performed before or after the operation with the intraocular lens.
  • Use of systemic or ocular medications that may affect vision in the last 6 months.
  • Subjects who participate in any clinical trial or research with drugs or medical devices within 30 days prior to entry into this research and/or during the period of participation in this research.

Patients implanted with AT Lisa Tri from March 2014 to June 2015